Argenx Se (ARGX) Total Current Liabilities (2015 - 2026)
Argenx Se's (ARGX) quarterly Total Current Liabilities came in at $1.6 billion in Q2 2026, down 99.85% YoY from $1041.9 billion in Q2 2025, and up 19.32% on a QoQ basis from $1.3 billion in Q4 2025.
Argenx Se (ARGX) Total Current Liabilities (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Total Current Liabilities data on file, last reported at $1.6 billion in Q2 2026.
- Quarterly Total Current Liabilities fell 99.85% year-over-year to $1.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (down 99.85% YoY) and the FY2025 annual result came in at $1.3 billion, up 97.04% from the prior year.
- Total Current Liabilities grew to $1.6 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1041.9 billion in Q2 2025 to a low of $264.6 million in Q2 2022.
- A 5-year average of $116.4 billion and a median of $499.6 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities jumped 208435.53% — and 2026, when it sank 99.85%.
- Tracing ARGX's Total Current Liabilities over 5 years: stood at $302.3 million in 2022, then soared by 39.94% to $423.0 million in 2023, then jumped by 58.38% to $669.9 million in 2024, then surged by 97.04% to $1.3 billion in 2025, then gained by 19.32% to $1.6 billion in 2026.
- The last three Total Current Liabilities figures came in at $1.6 billion (Q2 2026), $1.3 billion (Q4 2025), and $1041.9 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1,041.90 Bn |
| Dec 31, 2024 | 669.92 Mn |
| Jun 30, 2024 | 499.63 Mn |
| Dec 31, 2023 | 422.99 Mn |
| Jun 30, 2023 | 317.79 Mn |
| Dec 31, 2022 | 302.28 Mn |
| Jun 30, 2022 | 264.60 Mn |
| Dec 31, 2021 | 301.24 Mn |
| Jun 30, 2021 | 244.04 Mn |
| Dec 31, 2020 | 319.17 Mn |
| Jun 30, 2020 | 217.90 Mn |
| Dec 31, 2019 | 177.05 Mn |
| Jun 30, 2019 | 115.05 Mn |
| Dec 31, 2018 | 45.72 Mn |
| Jun 30, 2018 | 32.26 Mn |
| Dec 31, 2017 | 28.87 Mn |
| Jun 30, 2017 | 38.74 Mn |
| Dec 31, 2016 | 34.90 Mn |